Javascript doit fonctionner ! Activez-le et rechargez cette page.
Le Rézo de JeuxDeMots
• Types de relations
• Types de noeuds
• Consolider
le terme
  Options  
             

  Filtrage type relations : +   - (ex: 4, 12, 18, 36, 444, 555, 777)
  Filtrage valeur :          min   max
  Filtrage type noeuds :   +   - (ex: 4, 6, 8, 9, 10, 12, 18, 36, 444, 555, 777)

  Présentation de sortie :   (ex: -rien-, cloud, nicecloud)
 

'en:niacin-based antilipidemic agent'
(id=7188472 ; fe=en:niacin-based antilipidemic agent ; type=1 ; niveau=200 ; luminosité=25 ; somme entrante=920 creation date=2017-06-26 touchdate=2025-08-14 00:24:37.000)
≈ 21 relations sortantes

  1. en:niacin-based antilipidemic agent -- r_associated #0: 20 / 1 -> acide pidolique
    n1=en:niacin-based antilipidemic agent | n2=acide pidolique | rel=r_associated | relid=0 | w=20
  2. en:niacin-based antilipidemic agent -- r_associated #0: 20 / 1 -> acide pyroglutamique
    n1=en:niacin-based antilipidemic agent | n2=acide pyroglutamique | rel=r_associated | relid=0 | w=20
  3. en:niacin-based antilipidemic agent -- r_associated #0: 20 / 1 -> anacetrapib
    n1=en:niacin-based antilipidemic agent | n2=anacetrapib | rel=r_associated | relid=0 | w=20
  4. en:niacin-based antilipidemic agent -- r_associated #0: 20 / 1 -> en:anacetrapib
    n1=en:niacin-based antilipidemic agent | n2=en:anacetrapib | rel=r_associated | relid=0 | w=20
  5. en:niacin-based antilipidemic agent -- r_associated #0: 20 / 1 -> en:azacosterol hydrochloride
    n1=en:niacin-based antilipidemic agent | n2=en:azacosterol hydrochloride | rel=r_associated | relid=0 | w=20
  6. en:niacin-based antilipidemic agent -- r_associated #0: 20 / 1 -> en:azalanstat
    n1=en:niacin-based antilipidemic agent | n2=en:azalanstat | rel=r_associated | relid=0 | w=20
  7. en:niacin-based antilipidemic agent -- r_associated #0: 20 / 1 -> en:benzmalecene
    n1=en:niacin-based antilipidemic agent | n2=en:benzmalecene | rel=r_associated | relid=0 | w=20
  8. en:niacin-based antilipidemic agent -- r_associated #0: 20 / 1 -> en:eflucimibe
    n1=en:niacin-based antilipidemic agent | n2=en:eflucimibe | rel=r_associated | relid=0 | w=20
  9. en:niacin-based antilipidemic agent -- r_associated #0: 20 / 1 -> en:ethyl icosapentate
    n1=en:niacin-based antilipidemic agent | n2=en:ethyl icosapentate | rel=r_associated | relid=0 | w=20
  10. en:niacin-based antilipidemic agent -- r_associated #0: 20 / 1 -> en:ezetimibe
    n1=en:niacin-based antilipidemic agent | n2=en:ezetimibe | rel=r_associated | relid=0 | w=20
  11. en:niacin-based antilipidemic agent -- r_associated #0: 20 / 1 -> en:ezetimibe/simvastatin
    n1=en:niacin-based antilipidemic agent | n2=en:ezetimibe/simvastatin | rel=r_associated | relid=0 | w=20
  12. en:niacin-based antilipidemic agent -- r_associated #0: 20 / 1 -> en:hmg-coa reductase inhibitor
    n1=en:niacin-based antilipidemic agent | n2=en:hmg-coa reductase inhibitor | rel=r_associated | relid=0 | w=20
  13. en:niacin-based antilipidemic agent -- r_associated #0: 20 / 1 -> en:lifibrol
    n1=en:niacin-based antilipidemic agent | n2=en:lifibrol | rel=r_associated | relid=0 | w=20
  14. en:niacin-based antilipidemic agent -- r_associated #0: 20 / 1 -> en:lomitapide
    n1=en:niacin-based antilipidemic agent | n2=en:lomitapide | rel=r_associated | relid=0 | w=20
  15. en:niacin-based antilipidemic agent -- r_associated #0: 20 / 1 -> en:omega-3 acid ethyl esters (usp)
    n1=en:niacin-based antilipidemic agent | n2=en:omega-3 acid ethyl esters (usp) | rel=r_associated | relid=0 | w=20
  16. en:niacin-based antilipidemic agent -- r_associated #0: 20 / 1 -> en:pidolic acid
    n1=en:niacin-based antilipidemic agent | n2=en:pidolic acid | rel=r_associated | relid=0 | w=20
  17. en:niacin-based antilipidemic agent -- r_associated #0: 20 / 1 -> en:sorbinicate
    n1=en:niacin-based antilipidemic agent | n2=en:sorbinicate | rel=r_associated | relid=0 | w=20
  18. en:niacin-based antilipidemic agent -- r_associated #0: 20 / 1 -> en:sunagrel
    n1=en:niacin-based antilipidemic agent | n2=en:sunagrel | rel=r_associated | relid=0 | w=20
  19. en:niacin-based antilipidemic agent -- r_associated #0: 20 / 1 -> en:vytorin
    n1=en:niacin-based antilipidemic agent | n2=en:vytorin | rel=r_associated | relid=0 | w=20
  20. en:niacin-based antilipidemic agent -- r_associated #0: 20 / 1 -> ézétimibe
    n1=en:niacin-based antilipidemic agent | n2=ézétimibe | rel=r_associated | relid=0 | w=20
  21. en:niacin-based antilipidemic agent -- r_associated #0: 20 / 1 -> lomitapide
    n1=en:niacin-based antilipidemic agent | n2=lomitapide | rel=r_associated | relid=0 | w=20
≈ 25 relations entrantes

  1. acide pidolique --- r_associated #0: 74 --> en:niacin-based antilipidemic agent
    n1=acide pidolique | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=74
  2. acide pyroglutamique --- r_associated #0: 66 --> en:niacin-based antilipidemic agent
    n1=acide pyroglutamique | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=66
  3. en:pidolic acid --- r_associated #0: 66 --> en:niacin-based antilipidemic agent
    n1=en:pidolic acid | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=66
  4. en:lomitapide --- r_associated #0: 53 --> en:niacin-based antilipidemic agent
    n1=en:lomitapide | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=53
  5. ézétimibe --- r_associated #0: 50 --> en:niacin-based antilipidemic agent
    n1=ézétimibe | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=50
  6. en:ezetimibe --- r_associated #0: 49 --> en:niacin-based antilipidemic agent
    n1=en:ezetimibe | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=49
  7. lomitapide --- r_associated #0: 49 --> en:niacin-based antilipidemic agent
    n1=lomitapide | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=49
  8. en:eflucimibe --- r_associated #0: 42 --> en:niacin-based antilipidemic agent
    n1=en:eflucimibe | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=42
  9. en:azacosterol hydrochloride --- r_associated #0: 40 --> en:niacin-based antilipidemic agent
    n1=en:azacosterol hydrochloride | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=40
  10. en:azalanstat --- r_associated #0: 35 --> en:niacin-based antilipidemic agent
    n1=en:azalanstat | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=35
  11. en:sorbinicate --- r_associated #0: 35 --> en:niacin-based antilipidemic agent
    n1=en:sorbinicate | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=35
  12. en:omega-3 acid ethyl esters (usp) --- r_associated #0: 34 --> en:niacin-based antilipidemic agent
    n1=en:omega-3 acid ethyl esters (usp) | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=34
  13. en:vytorin --- r_associated #0: 34 --> en:niacin-based antilipidemic agent
    n1=en:vytorin | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=34
  14. anacetrapib --- r_associated #0: 30 --> en:niacin-based antilipidemic agent
    n1=anacetrapib | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=30
  15. en:anacetrapib --- r_associated #0: 30 --> en:niacin-based antilipidemic agent
    n1=en:anacetrapib | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=30
  16. en:hmg-coa reductase inhibitor --- r_associated #0: 29 --> en:niacin-based antilipidemic agent
    n1=en:hmg-coa reductase inhibitor | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=29
  17. en:sunagrel --- r_associated #0: 29 --> en:niacin-based antilipidemic agent
    n1=en:sunagrel | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=29
  18. en:lifibrol --- r_associated #0: 28 --> en:niacin-based antilipidemic agent
    n1=en:lifibrol | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=28
  19. en:ezetimibe/simvastatin --- r_associated #0: 27 --> en:niacin-based antilipidemic agent
    n1=en:ezetimibe/simvastatin | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=27
  20. en:benzmalecene --- r_associated #0: 26 --> en:niacin-based antilipidemic agent
    n1=en:benzmalecene | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=26
  21. en:ethyl icosapentate --- r_associated #0: 26 --> en:niacin-based antilipidemic agent
    n1=en:ethyl icosapentate | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=26
  22. en:probucol --- r_associated #0: 25 --> en:niacin-based antilipidemic agent
    n1=en:probucol | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=25
  23. en:pyroglutamic acid --- r_associated #0: 23 --> en:niacin-based antilipidemic agent
    n1=en:pyroglutamic acid | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=23
  24. Ézétimibe --- r_associated #0: 10 --> en:niacin-based antilipidemic agent
    n1=Ézétimibe | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=10
  25. évitement (conduite d') --- r_associated #0: 10 --> en:niacin-based antilipidemic agent
    n1=évitement (conduite d') | n2=en:niacin-based antilipidemic agent | rel=r_associated | relid=0 | w=10
Le service Rézo permet d'énumérer les relations existant pour un terme. Ce service est interrogeable par programme.
Projet JeuxDeMots - url: http://www.jeuxdemots.org
contact: mathieu.lafourcade@lirmm.fr